Nationwide Cohort Study of Antiretroviral Therapy Timing: Treatment Dropout and Virological Failure in China, 2011-2015.
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
01 01 2019
01 01 2019
Historique:
received:
24
01
2018
accepted:
04
05
2018
pubmed:
18
5
2018
medline:
21
1
2020
entrez:
18
5
2018
Statut:
ppublish
Résumé
People living with human immunodeficiency virus (PLWH) are still being diagnosed late, rendering the benefits of "early" antiretroviral therapy (ART) unattainable. Therefore, we aimed to evaluate the benefits of "immediate" ART. A nationwide cohort of PLWH in China who initiated ART January 1, 2011, to December 31, 2014 and had baseline CD4 results >200 cells/μL were censored at 12 months, dropout, or death, whichever came first. Treatment dropout and virological failure (viral load ≥400 copies/mL) were measured. Determinants were assessed by Cox and log-binomial regression. The cohort included 123605 PLWH. The ≤30 days group had a significantly lower treatment dropout rate of 6.72%, compared to 8.91% for the 91-365 days group and to 12.64% for the >365 days group. The ≤30 days group also had a significantly lower virological failure rate of 5.45% (31-90 days: 7.39%; 91-365 days: 9.64%; >365 days: 12.67%). Greater risk of dropout (91-365 days: adjusted hazard ratio [aHR] = 1.33, 95% confidence interval [CI] = 1.25-1.42; >365 days: aHR = 1.55, CI = 1.47-1.54), and virological failure (31-90 days: adjusted risk ratio [aRR] = 1.35, CI = 1.26-1.45; 91-365 days: aRR = 1.66, CI = 1.55-1.78; >365 days: aRR = 1.85, CI = 1.74-1.97) were observed for those who delayed treatment. ART within 30 days of HIV diagnosis was associated with significantly reduced risk of treatment failure, highlighting the need to implement test-and-immediately-treat policies.
Sections du résumé
Background
People living with human immunodeficiency virus (PLWH) are still being diagnosed late, rendering the benefits of "early" antiretroviral therapy (ART) unattainable. Therefore, we aimed to evaluate the benefits of "immediate" ART.
Methods
A nationwide cohort of PLWH in China who initiated ART January 1, 2011, to December 31, 2014 and had baseline CD4 results >200 cells/μL were censored at 12 months, dropout, or death, whichever came first. Treatment dropout and virological failure (viral load ≥400 copies/mL) were measured. Determinants were assessed by Cox and log-binomial regression.
Results
The cohort included 123605 PLWH. The ≤30 days group had a significantly lower treatment dropout rate of 6.72%, compared to 8.91% for the 91-365 days group and to 12.64% for the >365 days group. The ≤30 days group also had a significantly lower virological failure rate of 5.45% (31-90 days: 7.39%; 91-365 days: 9.64%; >365 days: 12.67%). Greater risk of dropout (91-365 days: adjusted hazard ratio [aHR] = 1.33, 95% confidence interval [CI] = 1.25-1.42; >365 days: aHR = 1.55, CI = 1.47-1.54), and virological failure (31-90 days: adjusted risk ratio [aRR] = 1.35, CI = 1.26-1.45; 91-365 days: aRR = 1.66, CI = 1.55-1.78; >365 days: aRR = 1.85, CI = 1.74-1.97) were observed for those who delayed treatment.
Conclusions
ART within 30 days of HIV diagnosis was associated with significantly reduced risk of treatment failure, highlighting the need to implement test-and-immediately-treat policies.
Identifiants
pubmed: 29771296
pii: 4996605
doi: 10.1093/cid/ciy400
pmc: PMC6293037
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
43-50Subventions
Organisme : NIMH NIH HHS
ID : P30 MH058107
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA036307
Pays : United States
Références
Lancet HIV. 2017 Dec;4(12):e555-e565
pubmed: 28867267
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):44-51
pubmed: 27434707
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
AIDS. 2014 Jan;28 Suppl 1:S35-46
pubmed: 24468945
J Int AIDS Soc. 2016 Oct 25;19(1):20926
pubmed: 27784509
Sci Rep. 2017 Jun 9;7(1):3129
pubmed: 28600549
AIDS. 2007 Dec;21 Suppl 8:S143-8
pubmed: 18172383
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
Int J Epidemiol. 2010 Aug;39(4):973-9
pubmed: 19556327
Lancet HIV. 2015 Aug;2(8):e335-43
pubmed: 26423376
Math Biosci. 2016 Oct;280:38-49
pubmed: 27474205
AIDS. 2015 Sep 10;29(14):1871-82
pubmed: 26165354
PLoS Med. 2013;10(9):e1001510
pubmed: 24137103
Lancet Infect Dis. 2014 Apr;14(4):281-90
pubmed: 24602844
PLoS Med. 2016 May 10;13(5):e1002015
pubmed: 27163694
AIDS. 2016 Nov 28;30(18):2855-2864
pubmed: 27603290
Clin Infect Dis. 2018 Mar 5;66(6):833-839
pubmed: 29216405
PLoS Med. 2015 Sep 08;12(9):e1001874
pubmed: 26348214
Clin Infect Dis. 2015 Apr 1;60(7):1128-30
pubmed: 25516184
Clin Infect Dis. 2016 Dec 15;63(12):1668-1676
pubmed: 27609756
Clin Infect Dis. 2018 Feb 10;66(5):727-734
pubmed: 29069362
Int J Epidemiol. 2010 Dec;39 Suppl 2:ii79-89
pubmed: 21113041
Sci Rep. 2016 Sep 06;6:32947
pubmed: 27597312
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103